Stockreport

Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain [Yahoo! Finance]

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years The Medicines and Healthcare products Regulatory Agenc [Read more]